Genmab
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Genmab and other ETFs, options, and stocks.About GMAB
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia.
CEOJan G. J. van de Winkel
CEOJan G. J. van de Winkel
Employees2,682
Employees2,682
HeadquartersCopenhagen, Central Denmark
HeadquartersCopenhagen, Central Denmark
Founded1998
Founded1998
Employees2,682
Employees2,682
GMAB Key Statistics
Market cap18.42B
Market cap18.42B
Price-Earnings ratio12.07
Price-Earnings ratio12.07
Dividend yield—
Dividend yield—
Average volume2.52M
Average volume2.52M
High today$28.84
High today$28.84
Low today$28.24
Low today$28.24
Open price$28.74
Open price$28.74
Volume2.03M
Volume2.03M
52 Week high$33.65
52 Week high$33.65
52 Week low$17.24
52 Week low$17.24
Stock Snapshot
As of today, Genmab(GMAB) shares are valued at $28.66. The company's market cap stands at 18.42B, with a P/E ratio of 12.07.
On 2025-11-09, Genmab(GMAB) stock moved within a range of $28.24 to $28.84. With shares now at $28.66, the stock is trading +1.5% above its intraday low and -0.6% below the session's peak.
Trading activity shows a volume of 2.03M, compared to an average daily volume of 2.52M.
The stock's 52-week range extends from a low of $17.24 to a high of $33.65.
The stock's 52-week range extends from a low of $17.24 to a high of $33.65.
Analyst ratings
65%
of 26 ratingsBuy
65.4%
Hold
30.8%
Sell
3.8%